Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on March 3, 2011, regarding an event that occurred on March 2, 2011. The filing addresses a change in the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of a corporate governance event and contains no financial performance data.
Material Changes
The material change reported is the departure of a director:
- Michael Brauser tendered his resignation as a member of the Board of Directors, effective immediately on March 2, 2011.
- The resignation was for personal reasons.
- There were no disagreements with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The only commentary provided is the Company's expression of thanks to Mr. Brauser for his service.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. Brauser's departure.
- Confirm whether a replacement director has been appointed or if the seat remains vacant.
- Review subsequent filings to ensure no undisclosed disagreements or related party transactions exist regarding the resignation.